Nuclear Medicine and Molecular Imaging

The Korean Society of Nuclear Medicine (대한핵의학회)
권호 표지

Radiopharmaceuticals for Neurotransmitter Imaging

뇌 신경물질 운반체 영상용 방사성의약품

  • Oh, Seung-Jun (Department of Nuclear Medicine, Asan Medical Center, University of Ulsan College of Medicine)
  • 오승준 (울산대학교 의과대학 서울아산병원 핵의학과)
  • Published : 2007.04.30
Download PDF
⟨ Previous Next ⟩

Abstract

Neurotransmitter imaging with radiopharmaceuticals plays major role for understanding of neurological and psychiatric disorders such as Parkinson's disease and depression. Radiopharmaceuticals for neurotransmitter imaging can be divided to dopamine transporter imaging radiopharmaceuticals and serotonin trnasporter imaging radiopharmaceuticals. Many kinds of new dopamine transporter imaging radiopharmcaeuticals has a tropane ring and they showed different biological properties according to the substituted functional group on tropane ring. After the first clinical trials with $[^{123}I]{\beta}-CIT$, alkyl chain substituent introduced to tropane ring amine to decrease time for imaging acquisition and to increase selectivity. From these results, $[^{123}I]PE2I$, [18F]FE-CNT, $[^{123}I]FP-CIT$ and $[^{18}F]FP-CIT$ were developed and they showed high uptake on the dopamine transporter rich regions and fast peak uptake equilibrium time within 4 hours after injection. $[^{11}C]McN$ 5652 was developed for serotonin trnasporter imaging but this compound showed slow kinetics and high background radioactivity. To overcome these problems, new diarylsulfide backbone derivatives such as ADAM, ODAM, AFM, and DASB were developed. In these candidates, $[^{11}C]AFM$ and $[^{11}C]DASB$ showed high binding affinity to serotonin transporter and fast in vivo kinetics. This paper gives an overview of current status on dopamine and serotonin transporter imaging radiopharmaceuitcals and the development of new lead compounds as potential radiopharmaceuticals by medicinal chemistry.

Keywords

References

  1. Piccini PP. Dopamine transporter: basic aspects and neuroimaging. Mov Disord 2003;18(Suppl 7):S3-8 https://doi.org/10.1002/mds.10338
  2. Au WL, Adams JR, Troiano AR, Stoessl AJ. Parkinson's disease: in vivo assessment of disease progression using positron emission tomography. Brain Res Mol Brain Res 2005;134:24-33 https://doi.org/10.1016/j.molbrainres.2004.09.028
  3. Neumeyer JL, Wang S, Gao Y, Milius RA, Kula NS, Campbell A, et al. N-$\omega$Fluoroalkyl analogs of (1R)-2$\beta$-carbomethoxy-3$\beta$ -(4-iodophenyl)-tropane ($\beta$-CIT): Radiotracers for positron emission tomography and single photon emission computed tomography imaging of dopamine transporter. J Med Chem 1994;37:1558-61 https://doi.org/10.1021/jm00037a004
  4. Kung HF, Kung MP, Choi SR. Radiopharmaceuticals for single-photon emission computed tomography brain imaging. Semin Nucl Med 2003;33:2-13 https://doi.org/10.1053/snuc.2003.127296
  5. Laruelle M, Baldwin RM, Malison RT, Zea-Ponce Y, Zoghbi SS, al-Tikriti MS, et al. SPECT imaging of dopamine and serotonin transporters with [123I]beta-CIT: pharmacological characterization of brain uptake in nonhuman primates. Synapse 1993;13:295-309 https://doi.org/10.1002/syn.890130402
  6. Frost JJ, Rosier AJ, Reich SG, Smith JS, Ehlers MD, Snyder SH, et al. Positron emission tomographic imaging of the dopamine transporter with $^{11}C$-WIN 35,428 revelas marked declines in mild Parkinson's disease. Ann Neurol 1993;34:423-31 https://doi.org/10.1002/ana.410340331
  7. Lundkvist C, Halldin C, Swahn CG, Hall H, Karlsson P, Nakashima Y, et al. [O-methyl-$^{11}C$]beta-CIT-FP, a potential radioligand for quantitation of the dopamine transporter: preparation, autoradiography, metabolite studies, and positron emission tomography examinations. Nucl Med Biol 1995;22:905-13 https://doi.org/10.1016/0969-8051(95)00029-W
  8. Huang WS, Lee MS, Lin JC, Chen CY, Yang YW, Lin SZ, et al. Usefulness of brain $^{99m}Tc$-TRODAT-1 SPET for the evaluation of Parkinson's disease. Eur J Nucl Med Mol Imaging 2004;31:155-61 https://doi.org/10.1007/s00259-003-1331-x
  9. Vanbilloen HP, Kieffer DM, Cleynhens BJ, Bormans GM, Mortelmans L, Verbruggen AM. Evaluation of $^{99m}Tc$-labeled tropanes with alkyl substituents on the 3beta-phenyl ring as potential dopamine transporter tracers. Nucl Med Biol 2006;33: 413-8 https://doi.org/10.1016/j.nucmedbio.2005.12.013
  10. Okada T, Fujita M, Shimada S, Sato K, Schloss P, Watanabe Y, Itoh Y, Tohyama M, Nishimura T. Assessment of affinities of beta-CIT, beta-CIT-FE, and beta-CIT-FP for monoamine transporters permanently expressed in cell lines. Nucl Med Biol 1998;25:53-8 https://doi.org/10.1016/S0969-8051(97)00156-X
  11. Lundkvist C, Halldin C, Ginovart N, Swahn CG, Farde L. [$^{18}F $] beta-CIT-FP is superior to [$^{11}C $] beta-CIT-FP for quantitation of the dopamine transporter. Nucl Med Biol 1997;24:621-7 https://doi.org/10.1016/S0969-8051(97)00077-2
  12. Goodman MM, Kilts CD, Keil R, Shi B, Martarello L, Xing D, et al. $^{18}F$-labeled FECNT: a selective radioligand for PET imaging of brain dopamine transporters. Nucl Med Biol 2000;27:1-12 https://doi.org/10.1016/S0969-8051(99)00080-3
  13. Zoghbi SS, Shetty HU, Ichise M, Fujita M, Imaizumi M, Liow JS, et al. PET imaging of the dopamine transporter with $^{18}F $-FECNT : apolar radiometabolite confounds brain radioligand measurements. J Nucl Med 2006;47:520-7
  14. Prunier C, Payoux P, Guilloteau D, Chalon S, Giraudeau B, Majorel C, et al. Quantification of dopamine transporter by $^{123}I $-PE2I SPECT and the noninvasive Logan graphical method in Parkinson's disease. J Nucl Med 2003;44:663-70
  15. Kim HJ, Im JH, Yang SO, Moon DH, Ryu JS, Bong JK, et al. Imaging and quantitation of dopamine transporters with iodine- 123-IPT in normal and Parkinson's disease subjects. J Nucl Med 1997;38:1703-11
  16. Dolle F, Emond P, Mavel S, Demphel S, Hinnen F, Mincheva Z, et al. Synthesis, radiosynthesis and in vivo preliminary evaluation of [$^{11}C $]LBT-999, a selective radioligand for the visualisation of the dopamine transporter with PET. Bioorg Med Chem 2006;14: 1115-25 https://doi.org/10.1016/j.bmc.2005.09.035
  17. Chalon S, Hall H, Saba W, Garreau L, Dolle F, Halldin C, et al. Pharmacological characterization of (E)-N-(4-fluorobut-2-enyl)-2betacarbomethoxy- 3beta-($4^+$-tolyl)nortropane (LBT-999) as a highly promising fluorinated ligand for the dopamine transporter. J Pharmacol Exp Ther 2006;317:147-52 https://doi.org/10.1124/jpet.105.096792
  18. Saba W, Valette H, Schollhorn-Peyronneau MA, Coulon C, Ottaviani M, Chalon S, et al. [${11}C$]LBT-999: a suitable radioligand for investigation of extra-striatal dopamine transporter with PET. Synapse 2007;61:17-23 https://doi.org/10.1002/syn.20337
  19. Dolle F, Hinnen F, Emond P, Mavel P, Mincheva Z, Saba W, et al. Radiosynthesis of [${18}F$]LBT-999, a selective radioligand for the visualization of the dopamine transporter with PET. J Label Compd Radiopharm 2006;49:687-98 https://doi.org/10.1002/jlcr.1092
  20. Chaly T, Dhawan V, Kazumata K, Antonini A, Margouleff C, Dahl JR, et al. Radiosynthesis of [$^{18}F$] N-3-fluoropropyl-2-betacarbomethoxy- -beta-(4-iodophenyl) nortropane and the first human study with positron emission tomography. Nucl Med Biol 1996; 23:999-1004 https://doi.org/10.1016/S0969-8051(96)00155-2
  21. Robeson W, Dhawan V, Belakhlef A, Ma Y, Pillai V, Chaly T, et al. Dosimetry of the dopamine transporter radioligand 18F-FPCIT in human subjects. J Nucl Med 2003;44:961-6
  22. Kim DW, Ahn DS, Oh YH, Lee S, Kil HS, Oh SJ, et al. A new class of ${SN}_2$ reactions catalyzed by protic solvents: Facile fluorination for isotopic labeling of diagnostic molecules. J Am Chem Soc 2006;128:16394-7 https://doi.org/10.1021/ja0646895
  23. Aquilonius SM, Bergstrom K, Eckernas SA, Hartvig P, Leenders KL, Lundkvist H, et al. In vivo evaluation of striatal dopamine reuptake sites using $^{11}C$-Nomifesin and positron emission tomography. Acta Neurol Scand 1987;76:283-87 https://doi.org/10.1111/j.1600-0404.1987.tb03582.x
  24. Booji J, Hemelaar J, Speelman JD, Bruin K, Janssen A, Royen EA. One-day protocol for imaging of the nigrostriatal dopaminergic pathway in Parkinson's disease by [$^{123}I$]FP-CIT SPECT. J Nucl Med 1999;40:753-61
  25. Kazumata K, Dhawan V, Chaly T, Antonini A, Margouleff C, Belakhlef A, et al. Dopamine transporter imaging with fluorine- 18-FPCIT and PET. J Nucl Med 1998;39:1521-30
  26. Lee SJ, Oh SJ, Kim JS, Chi DY, Lim KC, Lim SJ, et al. Preclinical studies of [F-18]Fluoropropyl-arbomethoxyIodonortropane (FP-CIT). 2006 World J Nucl Med 2006;5:S38
  27. Huang Y, Hwang DR, Narendran R, Sudo Y, Chatterjee R, Bae SA, et al. Comparative evaluation in nonhuman primates of five PET radiotracers for imaging the serotonin transporters: [$^{11}C$]McN 5652, [$^{11}C$]ADAM, [$^{11}C$]DASB, [$^{11}C$]DAPA, and [$^{11}C$]AFM. J Cereb Blood Flow Metab 2002;22:1377-98 https://doi.org/10.1097/01.WCB.0000040948.67415.05
  28. Hashimoto K, Inoue O, Suzuki K, Yamasaki T, Kojima M. Synthesis and evaluation of [$^{11}C$]cyanoimipramine. Int J Rad ApplInstrum [B] 1987;14:587-92
  29. Lasne MC, Pike VW, Turton DR. The radiosynthesis of [N-methyl-$^{11}C$]-sertraline. Int J Rad Appl Instrum [A] 1989;40: 147-51 https://doi.org/10.1016/0883-2889(89)90190-1
  30. Livni E, Satterlee W, Robey RL, Alt CA, Van Meter EE, Babich JW, et al. Synthesis of [$^{11}C$]dapoxetine.HCl, a serotonin re-uptake inhibitor: biodistribution in rat and preliminary PET imaging in the monkey. Nucl Med Biol 1994;21:669-75 https://doi.org/10.1016/0969-8051(94)90034-5
  31. Scheffel U, Dannals RF, Suehiro M, Ricaurte GA, Carroll FI, Kuhar MJ, et al. Development of PET/SPECT ligands for the serotonin transporter. NIDA Res Monogr 1994;138:111-30
  32. Dannals RF, Ravert HT, Wilson AA, Wagner HN Jr. Synthesis of a selective serotonin uptake inhibitor: [$^{11}C$]citalopram. Int J Rad Appl Instrum [A] 1990;41:541-43 https://doi.org/10.1016/0883-2889(90)90036-G
  33. Suehiro M, Scheffel U, Dannals RF, Wilson AA, Ravert HT, Wagner HN Jr. Synthesis and biodistribution of a new radiotracer for in vivo labeling of serotonin uptake sites by PET, cis-N,N-[$^{11}C$]dimethyl-3-(2',4'-dichlorophenyl)-indanamine (cis-[$^{11}C$]DDPI). Int J Rad Appl Instrum B. 1992;19:549-53 https://doi.org/10.1016/0883-2897(92)90150-W
  34. Zea-Ponce Y, Baldwin RM, Stratton MD, Al-Tikriti M, Souffer R, Schauss JM, et al. Radiosynthesis and PET imaging of [N-methyl-$^{11}C$]LY257327 as a tracer for 5-HT transporters. Nucl Med Biol 1997;24:251-54 https://doi.org/10.1016/S0969-8051(97)00062-0
  35. Smith DF, Jensen PN, Gee AD, Hansen SB, Danielsen E, Andersen F, et al. PET neuroimaging with [$^{11}C$]venlafaxine:serotonin uptake inhibition, biodistribution and binding in living pig brain. Eur Neuropsychopharmacol 1997;7:195-200 https://doi.org/10.1016/S0924-977X(97)00403-3
  36. Bergstrom KA, Halldin C, Hall H, Lundkvist C, Ginovart N, Swahn CG, et al. In vitro and in vivo characterisation of norbeta-CIT: a potential radioligand for visualisation of the serotonin transporter in the brain. Eur J Nucl Med 1997;24:596-601 https://doi.org/10.1007/BF00841395
  37. Jagust WJ, Eberling JL, Biegon A, Taylor SE, VanBrocklin HF, Jordan S, et al. Iodine-123-5-iodo-6-nitroquipazine: SPECT radiotracer to image the serotonin transporter. J Nucl Med 1996;37:1207-1214
  38. Lundkvist C, Loc'h C, Halldin C, Bottlaender M, Ottaviani M, Coulon C, et al. Characterization of bromine-76-labeled 5-bromo- 6-nitroquipazine for PET studies of the serotonin transporter. Nucl Med Biol 1999;26:501-507 https://doi.org/10.1016/S0969-8051(99)00019-0
  39. Suehiro M, Scheffel U, Ravert HT, Dannals RF, Wagner HN Jr. [$^{11}C$](+)McN5652 as a radiotracer for imaging serotonin uptake sites with PET. Life Sci 1993;53:883-92 https://doi.org/10.1016/0024-3205(93)90440-E
  40. Suehiro M, Wilson AA, Scheffel U, Dannals RF, Ravert HT, Wagner HN Jr. Radiosynthesis and evaluation of N-(3- [$^{18}F$]fluoropropyl)paroxetine as a radiotracer for in vivo labeling of serotonin uptake sites by PET. Int J Rad Appl Instrum B 1991;18:791-6 https://doi.org/10.1016/0883-2897(91)90019-H
  41. Oya S, Kung MP, Acton PD, Mu M, Hou C, Kung HF. A new single-photon emission computed tomography imaging agent for serotonin transporters: [$^{123}I$]IDAM, 5-iodo-2-((2-((dimethylamino) methyl)phenyl)thio)benzyl alcohol. J Med Chem 1999;42:333-5 https://doi.org/10.1021/jm9806751
  42. Oya S, Choi SR, Kung MP, Kung HF. 5-Chloro-2-(2'- ((dimethylamino) methyl)-4'-iodophenylthio) benzenamine: a new serotonin transporter ligand. Nucl Med Biol 2007;34:129-39 https://doi.org/10.1016/j.nucmedbio.2006.12.002
  43. Huang Y, Hwang DR, Zhu Z, Bae SA, Guo N, Sudo Y, et al. Synthesis and pharmacological characterization of a new PET ligand for the serotonin transporter: [$^{11}C$]5-bromo-2-[2-(dimethyl aminomethylphenylsulfanyl)] phenylamine ([$^{11}C$]DAPA). Nucl Med Biol 2002;29:741-51 https://doi.org/10.1016/S0969-8051(02)00337-2
  44. Wilson AA, Ginovart N, Hussey D, Meyer J, Houle S. In vitro and in vivo characterisation of [$^{11}C$]-DASB: a probe for in vivo measurements of the serotonin transporter by positron emission tomography. Nucl Med Biol 2002;29:509-15 https://doi.org/10.1016/S0969-8051(02)00316-5
  45. Zhu Z, Guo N, Narendran R, Erritzoe D, Ekelund J, Hwang DR, et al. The new PET imaging agent [11C]AFE is a selective serotonin transporter ligand with fast brain uptake kinetics. Nucl Med Biol 2004;31:983-94 https://doi.org/10.1016/j.nucmedbio.2004.07.003
  46. Huang Y, Hwang DR, Bae SA, Sudo Y, Guo N, Zhu Z, et al. Anew positron emission tomography imaging agent for the serotonin transporter: synthesis, pharmacological characterization, and kinetic analysis of [$^{11}C$]2-[2-(dimethylaminomethyl)phenylthio]-5-fluoromethylphenylam ine ([$^{11}C$]AFM). Nucl Med Biol 2004;31:543-56 https://doi.org/10.1016/j.nucmedbio.2003.11.008
  47. Huang Y, Narendran R, Bae SA, Erritzoe D, Guo N, Zhu Z, et al. A PET imaging agent with fast kinetics: synthesis and in vivo evaluation of the serotonin transporter ligand [$^{11}C$]2-[2-dimethylaminomethyl phenylthio)]-5-fluorophenylamine ([$^{11}C$]AFA). Nucl Med Biol 2004;31:727-38 https://doi.org/10.1016/j.nucmedbio.2004.03.010
  48. Vercouillie J, Mavel S, Galineau L, Ragusa T, Innis R, Kassiou M, et al. Synthesis and in vitro evaluation of novel derivatives of diphenylsulfide as serotonin transporter ligands. Bioorg Med Chem Lett 2006;16:1297-300 https://doi.org/10.1016/j.bmcl.2005.11.066
  49. Jarkas N, McConathy J, Voll RJ, Goodman MM. Synthesis, in vitro characterization, and radiolabeling of N,N-dimethyl-2-(2'-amino-4'- substituted-phenylthio) benzylamines: potential candidates as selective serotonin transporter radioligands. J Med Chem 2005; 48:4254-65 https://doi.org/10.1021/jm050079o
  50. Huang Y, Bae SA, Zhu Z, Guo N, Roth BL, Laruelle M. Fluorinated diaryl sulfides as serotonin transporter ligands: synthesis, structure-activity relationship study, and in vivo evaluation of fluorine-18-labeled compounds as PET imaging agents. J Med Chem 2005;48:2559-70 https://doi.org/10.1021/jm0400808